Table 1. Association between PC2 (outcome) and lung adenocarcinoma tumour features in univariate and multivariate models (n=343).
| Non-molecular features | ||||||
|---|---|---|---|---|---|---|
| Predictors | Univariate model | Multivariate model | ||||
| OR/Beta (SE) | p-value | OR/Beta (SE) | p-value | |||
| Age at diagnosis* | 0.17±0.05 | 0.001 | 0.17±0.05 | 0.001 | ||
| Gender (male)† | 0.73±0.11 | 0.005 | 0.74±0.11 | 0.005 | ||
| Smoking status (ever)† | 0.67±0.16 | 0.013 | 0.72±0.15 | 0.035 | ||
| Tumour stage (late)† | 0.67±0.13 | 0.002 | 0.67±0.13 | 0.002 | ||
| Molecular features | ||||||
| Predictors | Univariate model | Multivariate model | ||||
| Beta (SE) | p-value | Beta (SE) | p-value | |||
| LTL PRS ‡ | 0.17±0.05 | 0.001 | 0.10±0.04 | 0.009 | ||
| Telomerase activity | –0.37±0.05 | 9.34E-13 | 0.25±0.06 | 1.32E-05 | ||
| Proliferation | –0.69±0.04 | 3.30E-46 | –0.80±0.06 | 3.66E-30 | ||
| Copy number alteration | –0.41±0.05 | 6.36E-16 | –0.23±0.05 | 1.62E-05 | ||
| Homologous recombination deficiency | –0.4±0.05 | 8.32E-15 | 0.12±0.06 | 0.048 | ||
| Tumour total mutation burden | –0.28±0.05 | 1.37E-07 | –0.09±0.24 | 0.695 | ||
| SBS1 | –0.18±0.05 | 0.001 | 0.01±0.05 | 0.827 | ||
| SBS4 | –0.24±0.05 | 6.36E-06 | 0.04±0.18 | 0.814 | ||
| SBS5 | –0.27±0.05 | 4.84E-07 | 0.03±0.09 | 0.770 | ||
SBS (single base substitution DNA mutational signatures); LTL = leukocyte telomere length; PC = principal component; PRS = polygenic risk score.
*
age of diagnosis represented as beta estimate per 1 unit of SD.
†
OR per 1 unit of SD.
‡
LTL PRS is adjusted by first five PC of genetic ancestry in the univariate model.